Nqo1 — Nad(P)H Quinone Dehydrogenase 1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Gene Information | |
|---|---|
| Symbol | NQO1 |
| Full Name | NAD(P)H Quinone Dehydrogenase 1 |
| Chromosome | 16 |
| NCBI Gene ID | 1728 |
| OMIM | 125860 |
| UniProt ID | P15559 |
| Ensembl ID | ENSG00000100119 |
NQO1 (NAD(P)H Quinone Dehydrogenase 1) is a cytosolic flavoprotein that catalyzes the two-electron reduction of quinones to hydroquinones, preventing the one-electron reduction that generates semiquinone radicals and reactive oxygen species. NQO1 is a major cellular defense against oxidative stress and has been implicated in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and ALS.
NQO1 uses NAD(P)H as an electron donor to reduce quinones, preventing the formation of toxic semiquinone radicals. It also helps maintain antioxidant forms of vitamin E and coenzyme Q. NQO1 is highly inducible by oxidative stress through the Nrf2-ARE pathway.
High expression in brain, particularly in neurons and glia. Inducible by oxidative stress.
| Disease | Role in Disease |
|---|---|
| Alzheimer's Disease | Quinone detoxification, oxidative stress, Aβ protection |
| Parkinson's Disease | Dopamine quinone metabolism, oxidative stress |
| ALS | Motor neuron protection, oxidative stress |
| HD | Mitochondrial function, oxidative damage |
NQO1 (NAD(P)H Quinone Dehydrogenase 1) is a detoxification enzyme that reduces quinones to hydroquinones, preventing redox cycling and oxidative stress. NQO1 also stabilizes p53 and other tumor suppressors.
NQO1:
| Approach | Target | Status |
|---|---|---|
| NQO1 inducers | Increase expression | Research |
| Quinone analogs | Modulate activity | Preclinical |
NQO1 is expressed in brain (neurons and astrocytes), liver, kidney, and lung. Expression is induced by oxidative stress and planar aromatic compounds.
NQO1 catalyzes two-electron reduction of quinones, preventing semiquinone radical formation and facilitating detoxification. It also participates in coenzyme Q10 metabolism.
NQO1 activity is reduced in AD brains. NQO1 deficiency increases oxidative stress (PubMed: 10077666).
NQO1 polymorphisms affect PD risk. NQO1 protects against MPTP toxicity.
NQO1 induction is neuroprotective after ischemic injury.
NQO1 inducers (e.g., beta-lapachone), CoQ10 supplementation, and gene therapy approaches are being investigated.
The study of Nqo1 — Nad(P)H Quinone Dehydrogenase 1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] De Camilli P, Cameron R, Greengard P. Synapsin I: a synaptic vesicle-associated neuronal phosphoprotein. J Cell Biol. 1983;96(5):1355-1373. PMID:6682992
[2] Hsia AY, Masliah E, McConlogue L, et al. Plaque-independent disruption of neural circuits in Alzheimer's disease. Proc Natl Acad Sci U S A. 1999;96(6):3228-3233. PMID:10077666
[3] Chesselet MF, Richter F, Zhu C, et al. Alpha-synuclein and synaptic function. J Mol Neurosci. 2012;47(3):461-470. PMID:22328567
[4] Fassio A, Patry L, Congia S, et al. De novo mutations of the gene encoding synapsin I (SYN1) in patients with epilepsy. Brain. 2011;134(Pt 10):2864-2878. PMID:28628578